CBL Syndrome clinical trials at UCSF

1 research study open to eligible people

CBL syndrome involves genetic changes that affect blood formation. UCSF is conducting a trial of trametinib and azacitidine for juvenile myelomonocytic leukemia. Researchers will assess if this combination treatment is safe and effective for patients.

Showing trials for

  • Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

    open to eligible people ages 1 month to 21 years

    This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with juvenile myelomonocytic leukemia (JMML). Newly diagnosed lower-risk JMML patients will receive trametinib and azacitidine. High-risk JMML patients will receive trametinib, azacitidine, fludarabine, and cytarabine.

    San Francisco, California and other locations

Last updated: